Conclusion
It has been suggested that reforms are necessary to speed up the drug approval process. However, in the interests of the health of the American public, it is essential that safety is not compromised in reform. There is evidence that the FDA has responded to the criticisms concerning the time of the approval process. The FDA has already reported decreases in review time since the enactment of the Prescription Drug User Fee Act of 1992. Drugs that can be used in the treatment of life-threatening diseases can be available before formal drug approval through the Treatment INDs. In the past, the approval was much slower, as evidenced by the beta blocker example. However, looking the present, it is clear that the approval process is effective and speedy when necessary. The FDA continues to be receptive to new suggestions to accelerate the approval process without compromising safety. In order to achieve the FDA's goal of protecting the health of Americans, it is important that drugs are safe and effective, but it also essential that drugs be made available to public in reasonable time.